Brind.

DaVita and Archer Daniels Midland Gain Over 30% YTD Stock Performance

1 report, 1 independent Updated Sep 21
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

DaVita and Archer Daniels Midland both achieved year-to-date gains of over 30% in their stock prices as of September 21, 2026. DaVita's growth is supported by improved reimbursement rates and cost discipline, with analysts projecting further earnings growth. Meanwhile, Archer Daniels Midland raised its guidance despite operating amid volatile global trade conditions.

From yahoo.com

Why it matters

Some supportBrind's analysis of the reports

The performance highlights the operational strengths of companies outside the dominant AI sector. For DaVita, the growth is tied to its specialized kidney dialysis business. For Archer Daniels Midland, the performance reflects its ability to navigate global commodity market risks.

From yahoo.com

Who's involved

  • DaVitaRenal dialysis company whose stock performance was noted.
  • Archer Daniels MidlandGlobal food processing and commodities trading corporation whose stock performance was noted.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Berkshire Hathaway could see the value of its substantial equity stake in DaVita increase due to the company's strong performance.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped